These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 9116394)

  • 1. Role of oral pamidronate in preventing bone loss in postmenopausal women.
    Lees B; Garland SW; Walton C; Ross D; Whitehead MI; Stevenson JC
    Osteoporos Int; 1996; 6(6):480-5. PubMed ID: 9116394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis.
    Orr-Walker B; Wattie DJ; Evans MC; Reid IR
    Clin Endocrinol (Oxf); 1997 Jan; 46(1):87-92. PubMed ID: 9059563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
    Thiébaud D; Burckhardt P; Kriegbaum H; Huss H; Mulder H; Juttmann JR; Schöter KH
    Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis.
    Fromm GA; Vega E; Plantalech L; Galich AM; Mautalen CA
    Osteoporos Int; 1991 Jun; 1(3):129-33. PubMed ID: 1790400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis.
    Reid IR; Wattie DJ; Evans MC; Gamble GD; Stapleton JP; Cornish J
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1595-9. PubMed ID: 7989461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Site-dependent bone mineral density response to oral pamidronate and calcium in postmenopausal osteoporosis: a preliminary report.
    Barreira JC; Messina OD; Maldonado-Cocco JA; Roldan EJ
    Clin Rheumatol; 1997 Jun; 16(4):346-52. PubMed ID: 9259247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety.
    Ryan PJ; Blake GM; Davie M; Haddaway M; Gibson T; Fogelman I
    Osteoporos Int; 2000; 11(2):171-6. PubMed ID: 10793877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial.
    Boutsen Y; Jamart J; Esselinckx W; Stoffel M; Devogelaer JP
    Calcif Tissue Int; 1997 Oct; 61(4):266-71. PubMed ID: 9312195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group.
    Delmas PD; Pornel B; Felsenberg D; Garnero P; Hardy P; Pilate C; Dain MP
    Bone; 1999 May; 24(5):517-23. PubMed ID: 10321913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study.
    Ravn P; Clemmesen B; Riis BJ; Christiansen C
    Bone; 1996 Nov; 19(5):527-33. PubMed ID: 8922653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause.
    Thiébaud D; Burckhardt P; Melchior J; Eckert P; Jacquet AF; Schnyder P; Gobelet C
    Osteoporos Int; 1994 Mar; 4(2):76-83. PubMed ID: 8003844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis.
    Rossini M; Gatti D; Zamberlan N; Braga V; Dorizzi R; Adami S
    J Bone Miner Res; 1994 Nov; 9(11):1833-7. PubMed ID: 7863833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study.
    Herd RJ; Balena R; Blake GM; Ryan PJ; Fogelman I
    Am J Med; 1997 Aug; 103(2):92-9. PubMed ID: 9274891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on bone mass after eight years of hormonal replacement therapy.
    Eiken P; Nielsen SP; Kolthoff N
    Br J Obstet Gynaecol; 1997 Jun; 104(6):702-7. PubMed ID: 9197874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spine and femur BMD by DXA in patients with varying severity spinal osteoporosis.
    Ryan PJ; Blake GM; Herd R; Parker J; Fogelman I
    Calcif Tissue Int; 1993 Apr; 52(4):263-8. PubMed ID: 8467405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study.
    Krieg MA; Seydoux C; Sandini L; Goy JJ; Berguer DG; Thiébaud D; Burckhardt P
    Osteoporos Int; 2001; 12(2):112-6. PubMed ID: 11303710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.